Blood Res.  2024;59:26. 10.1007/s44313-024-00030-w.

Functional iron deficiency anemia in patients with cancer

• Koh J
• Song I

• KMID: 2562530
• DOI: http://doi.org/10.1007/s44313-024-00030-w

Abstract

Anemia is frequently observed in patients with cancer owing to anticancer chemotherapy, radiation therapy, and inflammatory responses. This often leads to functional iron deficiency, characterized by adequate iron stores but impaired use of iron for red blood cell production. This condition, termed functional iron deficiency anemia (IDA), is identified by a ferritin level of 30–500 µg/dL and a transferrin saturation < 50%. Functional iron deficiency often develops with the prolonged use of erythropoiesis-stimulating agents, leading to a diminished response to anemia treatment. Although oral iron supplementation is common, intravenous iron is more effective and recommended in such cases. Recent studies have shown that ferric carboxymaltose (FCM) is effective in treating functional IDA in patients with cancer. However, because of its potential to induce asymptomatic severe phosphate deficiency, it is important to closely monitor phosphate levels in patients receiving FCM.

Keyword

Functional iron deficincy; Anemia; Cancer; Hepcidin

Figure

• 

  Fig. 1 Mechanism by which hepcidin inhibits iron export through ferroportin

Reference

1. Cappellini MD, Musallam KM, Taher AT. 2020; Iron deficiency anaemia revisited. J Intern Med. 287(2):153–70. DOI: 10.1111/joim.13004. PMID: 31665543.

2. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. 2016; Iron deficiency anaemia. Lancet. 387(10021):907–16. DOI: 10.1016/S0140-6736(15)60865-0. PMID: 26314490.

3. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. 2021; Iron deficiency. Lancet. 397(10270):233–48. DOI: 10.1016/S0140-6736(20)32594-0. PMID: 33285139.

4. Lee JO, Lee JH, Ahn S, Kim JW, Chang H, Kim YJ, et al. 2014; Prevalence and risk factors for iron deficiency anemia in the Korean population: results of the fifth Korea National Health and nutrition examination survey. J Korean Med Sci. 29(2):224–9. DOI: 10.3346/jkms.2014.29.2.224. PMID: 24550649. PMCID: PMC3924001.

5. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. 2017; Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 390(10100):1211–59. DOI: 10.1016/S0140-6736(17)32154-2. PMID: 28919117.

6. Andrews NC. 1999; Disorders of iron metabolism. N Engl J Med. 341(26):1986–95. DOI: 10.1056/NEJM199912233412607. PMID: 10607817.

7. Oliveira F, Rocha S, Fernandes R. 2014; Iron metabolism: from health to disease. J Clin Lab Anal. 28(3):210–8. DOI: 10.1002/jcla.21668. PMID: 24478115. PMCID: PMC6807557.

8. Silva B, Faustino P. 2015; An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim Biophys Acta. 1852(7):1347–59. DOI: 10.1016/j.bbadis.2015.03.011. PMID: 25843914.

9. Short MW, Domagalski JE. 2013; Iron deficiency anemia: evaluation and management. Am Fam Phys. 87(2):98–104.

10. DeLoughery TG. 2014; Microcytic anemia. N Engl J Med. 371(14):1324–31. DOI: 10.1056/NEJMra1215361. PMID: 25271605.

11. Yhim HY, Kwak JY. 2015; Treatment of iron-deficiency anemia. Korean J Med. 89(1):43–7. DOI: 10.3904/kjm.2015.89.1.43.

12. Bjørklund G, Peana M, Pivina L, Dosa A, Aaseth J, Semenova Y, et al. 2021; Iron deficiency in obesity and after bariatric surgery. Biomolecules. 11(5):613. DOI: 10.3390/biom11050613. PMID: 33918997. PMCID: PMC8142987.

13. Steenackers N, Van der Schueren B, Mertens A, Lannoo M, Grauwet T, Augustijns P, Matthys C. 2018; Iron deficiency after bariatric surgery: what is the real problem? Proc Nutr Soc. 77(4):445–55. DOI: 10.1017/S0029665118000149. PMID: 29619914.

14. Sekiguchi M, Oda I, Matsuda T, Saito Y. 2022; Epidemiological trends and future perspectives of gastric cancer in Eastern Asia. Digestion. 103(1):22–8. DOI: 10.1159/000518483. PMID: 34515086.

15. Eisenga MF, Bakker SJL, Gaillard CAJM. 2016; Definition of functional iron deficiency and intravenous iron supplementation. Lancet Haematol. 3(11):e504. DOI: 10.1016/S2352-3026(16)30152-1. PMID: 27968819.

16. Camaschella C. 2015; Iron deficiency: new insights into diagnosis and treatment. Hematol Am Soc Hematol Educ Program. 2015:8–13. DOI: 10.1182/asheducation-2015.1.8. PMID: 26637694.

17. Camaschella C, Nai A, Silvestri L. 2020; Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 105(2):260–72. DOI: 10.3324/haematol.2019.232124. PMID: 31949017. PMCID: PMC7012465.

18. Ganz T, Nemeth E. 2012; Hepcidin and iron homeostasis. Biochim Biophys Acta. 1823(9):1434–43. DOI: 10.1016/j.bbamcr.2012.01.014. PMID: 22306005. PMCID: PMC4048856.

19. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. 2000; LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480(2-3):147–50. DOI: 10.1016/S0014-5793(00)01920-7. PMID: 11034317.

20. Qiao B, Sugianto P, Fung E, Del-Castillo-Rueda A, Moran-Jimenez MJ, Ganz T, et al. 2012; Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. 15(6):918–24. DOI: 10.1016/j.cmet.2012.03.018. PMID: 22682227. PMCID: PMC3372862.

21. Aschemeyer S, Qiao B, Stefanova D, Valore EV, Sek AC, Ruwe TA, et al. 2018; Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood. 131(8):899–910. DOI: 10.1182/blood-2017-05-786590. PMID: 29237594. PMCID: PMC5824336.

22. Billesbølle CB, Azumaya CM, Kretsch RC, Powers AS, Gonen S, Schneider S, et al. 2020; Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms. Nature. 586(7831):807–11. DOI: 10.1038/s41586-020-2668-z. PMID: 32814342. PMCID: PMC7906036.

23. Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, et al. 2023; Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med. 389(11):975–86. DOI: 10.1056/NEJMoa2304968. PMID: 37632463.

24. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. 2009; Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 361(25):2436–48. DOI: 10.1056/NEJMoa0908355. PMID: 19920054.

25. Khalafallah AA, Yan C, Al-Badri R, Robinson E, Kirkby BE, Ingram E, et al. 2016; Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Lancet Haematol. 3(9):e415–25. DOI: 10.1016/S2352-3026(16)30078-3. PMID: 27570088.

26. Gilreath JA, Stenehjem DD, Rodgers GM. 2014; Diagnosis and treatment of cancer-related anemia. Am J Hematol. 89(2):203–12. DOI: 10.1002/ajh.23628. PMID: 24532336.

27. Gilreath JA, Rodgers GM. 2020; How I treat cancer-associated anemia. Blood. 136(7):801–13. DOI: 10.1182/blood.2019004017. PMID: 32556170.

28. Kim HJ, Hwang SH, Oh HB, Ko DH. 2023; Transfusion thresholds: the need for a patient-centered approach in hematologic disorders that require chronic transfusion therapy. Blood Res. 58(S 1):S8–10. DOI: 10.5045/br.2023.2023009. PMID: 36843379. PMCID: PMC10133846.

29. Carson JL, Carless PA, Hebert PC. 2012; Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 4(4):CD002042. DOI: 10.1002/14651858.CD002042.pub3.

30. Ludwig H, Aapro M, Bokemeyer C, Macdonald K, Soubeyran P, Turner M, et al. 2009; Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer. 45(9):1603–15. DOI: 10.1016/j.ejca.2009.02.003. PMID: 19278851.

31. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Epoetin Alfa Study Group. 2001; Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 19(11):2865–74. DOI: 10.1200/JCO.2001.19.11.2865. PMID: 11387359.

32. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. 2002; Doubleblind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 94(16):1211–20. DOI: 10.1093/jnci/94.16.1211. PMID: 12189224.

33. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. 2012; Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 12(12):CD003407. DOI: 10.1002/14651858.CD003407.pub5. PMID: 23235597. PMCID: PMC8145276.

34. Pirker R, Hedenus M, Vansteenkiste J, Hernandez E, Belton L, Terwey JH. 2016; Effectiveness of darbepoetin alfa for chemotherapy-induced anemia when initiated at hemoglobin ≤10 g/dL. Clin Ther. 38(1):122–135.e6. DOI: 10.1016/j.clinthera.2015.11.012. PMID: 26730453.

35. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. 2008; Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 299(8):914–24. DOI: 10.1001/jama.299.8.914. PMID: 18314434.

36. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. 2005; Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving firstline chemotherapy: a survival study. J Clin Oncol. 23(25):5960–72. DOI: 10.1200/JCO.2005.06.150. PMID: 16087945.

37. Smith RE Jr, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, et al. 2008; Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 26(7):1040–50. DOI: 10.1200/JCO.2007.14.2885. PMID: 18227526.

38. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. 2004; Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 22(7):1301–7. DOI: 10.1200/JCO.2004.08.119. PMID: 15051778.

39. Bastit L, Vandebroek A, Altintas S, Gaede B, Pintér T, Suto TS, et al. 2008; Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 26(10):1611–8. DOI: 10.1200/JCO.2006.10.4620. PMID: 18375890.

40. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, et al. 2011; Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 29(1):97–105. DOI: 10.1200/JCO.2010.30.3644. PMID: 21098317. PMCID: PMC3055863.

41. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, et al. 2013; Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 24(2):475–82. DOI: 10.1093/annonc/mds338. PMID: 23071262. PMCID: PMC3551483.

42. Toledano A, Luporsi E, Morere JF, Scotté F, Laribi K, Barrière J, et al. 2016; Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care Cancer. 24(1):67–75. DOI: 10.1007/s00520-015-2728-3. PMID: 25921449.

43. Verhaeghe L, Bruyneel L, Stragier E, Ferrante M, Dierickx D, Prenen H. 2017; The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: a retrospective study. Ann Gastroenterol. 30(6):654–63. DOI: 10.20524/aog.2017.0189. PMID: 29118560. PMCID: PMC5670285.

44. Keeler BD, Simpson JA, Ng O, Padmanabhan H, Brookes MJ, Acheson AG. IVICA Trial Group. 2017; Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. Br J Surg. 104(3):214–21. DOI: 10.1002/bjs.10328. PMID: 28092401.

45. Talboom K, Borstlap WAA, Roodbeen SX, Bruns ERJ, Buskens CJ, Hompes R, et al. 2023; Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open-label, randomised, controlled trial. Lancet Haematol. 10(4):e250–60. DOI: 10.1016/S2352-3026(22)00402-1. PMID: 36863386.

46. Richards T, Baikady RR, Clevenger B, Butcher A, Abeysiri S, Chau M, et al. 2020; Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. Lancet. 396(10259):1353–61. DOI: 10.1016/S0140-6736(20)31539-7. PMID: 32896294.

47. Silverstein SB, Rodgers GM. 2004; Parenteral iron therapy options. Am J Hematol. 76(1):74–8. DOI: 10.1002/ajh.20056. PMID: 15114602.

48. Klein K, Asaad S, Econs M, Rubin JE. 2018; Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep. 2018:bcr2017222851. DOI: 10.1136/bcr-2017-222851. PMID: 29298794. PMCID: PMC5775795.

49. Zoller H, Schaefer B, Glodny B. 2017; Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 26(4):266–75. DOI: 10.1097/MNH.0000000000000329. PMID: 28399017.